REGULATION OF NK ACTIVITY BY THE ADMINISTRATION OF BROMOCRIPTINE IN HALOPERIDOL-TREATED MICE

Citation
H. Nozaki et al., REGULATION OF NK ACTIVITY BY THE ADMINISTRATION OF BROMOCRIPTINE IN HALOPERIDOL-TREATED MICE, Brain, behavior, and immunity, 10(1), 1996, pp. 17-26
Citations number
34
Categorie Soggetti
Neurosciences,Immunology
ISSN journal
08891591
Volume
10
Issue
1
Year of publication
1996
Pages
17 - 26
Database
ISI
SICI code
0889-1591(1996)10:1<17:RONABT>2.0.ZU;2-I
Abstract
Haloperidol (HPD) is a dopamine receptor blocker and a major causative agent of neuroleptic malignant syndrome. To investigate the influence of HPD on immune responsiveness, the natural killer (NK) cell activit y of mice was examined after intraperitoneal administration of HPD for 5 days. NK cell activity was markedly decreased without a depletion o f NK cells. Bromocriptine (BROMO), which is used for the treatment of neuroleptic malignant syndrome, also decreased NK cell activity. The s uppressive effect on NK cell activity was inhibited by injecting both HPD and BROMO simultaneously. Serum levels of prolactin (PRL) decrease d after BROMO injection, although serum PRL level was not decreased af ter the combined administration of HPD and BROMO agents. The reduction of NK cell activity caused by BROMO and by HPD was prevented by the c o-injection of PRL and by a beta-adrenergic blocker, respectively. The se results indicate that HPD decreases NK cell activity in a PRL-indep endent manner and that BROMO decreases it via PRL reduction. It seems that the PRL-independent suppressive effect of HPD on NK cells, which is neutralized by BROMO, is mediated by splenic sympathetic function v ia the beta-adrenergic receptor system. Therefore, BROMO helps to alle viate the depressed NK cell activity caused by HPD therapy. (C) 1996 A cademic Press, Inc.